Search results
Huawei And Optica Foundation Forced To Cut Ties Due To The Discovery Of Their Involvement,...
Wccftech· 12 hours agoFor two years, Huawei had been funding U.S. research and awarded scientists millions in prize money....
Optica Cuts Ties With Huawei After Secret Funding Exposed
Bloomberg via Yahoo Finance· 1 day ago(Bloomberg) -- The Optica Foundation will no longer accept money from Huawei Technologies Co. for a...
Amgen's drug meets main goal in late-stage study for rare disease
Reuters· 3 days ago, opens new tab said on Wednesday its drug helped to reduce the risk of flares in patients with an...
Biotech Stock Roundup: GSK's Litigation Update, BIIB's Drug Approval & Other Updates
Zacks via Yahoo Finance· 2 days agoThis drug is currently approved for Neuromyelitis Optica Spectrum Disorder (NMOSD) in the United...
Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease
Zacks via Yahoo Finance· 2 days agoData from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a...
Amgen reports positive data from Phase III IgG4-RD treatment trial
Clinical Trials Arena via Yahoo Finance· 2 days agoAll key secondary endpoints were also achieved without any new safety signals. Furthermore, the...
Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal
Benzinga via Yahoo Finance· 2 days agoOn Wednesday, Amgen Inc (NASDAQ:AMGN) announced topline results from its Phase 3 trial evaluating...
Amgen's Uplizna Hits Phase 3 Endpoints in IgG4-RD
Market Watch· 3 days agoBy Colin Kellaher Amgen on Wednesday said a late-stage study of its autoimmune drug Uplizna hit its key goals in the treatment of immunoglobulin G4-related...